Clinical Trial Detail

NCT ID NCT02006485
Title Ublituximab in Combination With TGR-1202 in Patients With B-cell Malignancies
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors TG Therapeutics, Inc.
Indications

CLL/SLL

B-cell lymphoma

Therapies

Ublituximab + Umbralisib

Ibrutinib

Age Groups: adult

No variant requirements are available.